

## Pluristem Life Systems, Inc. (OTC BB: PLRS)



Pluristem Life Systems, Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for

the treatment of numerous severe degenerative, malignant and autoimmune disorders. The company's research and manufacturing facilities are located in Israel. Having recently purchased patents for its innovative stem cell production technology from the Technion-Israel Institute of Technology and the Weizmann Institute of Science, replacing previous license arrangements, Pluristem is positioned to take full advantage of opportunities in the \$30 billion therapeutic and regenerative cellular market.

Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the company's proprietary PluriX™ 3D bioreactor that imitates the natural micro-structure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. The resultant placental expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types. The PLX cells are also immune-privileged to protect the recipient from immunological reactions that often accompany transplant therapies. Using PluriX™, the company estimates it can produce up to 1,000 patient doses per placenta at a significantly lower cost than current methods.

The company's first planned product, PLX-I, targets a \$2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).

CURRENT PRICE: \$0.10  
 52-WEEK RANGE: \$0.01 - \$0.15  
 AVG DAILY VOLUME (90-DAY): 7,262,470  
 OUTSTANDING SHARES: 840.4 million  
**MARKET CAPITALIZATION: \$84.0 million**

### INCOME STATEMENT HIGHLIGHTS

REVENUE: Nil  
 NET INCOME: (\$5.8 million)  
 EPS (Diluted): (\$0.04)

All figures twelve months trailing as of March 31, 2007

### BALANCE SHEET HIGHLIGHTS

CASH & EQUIVALENTS: \$4.6 million  
 WORKING CAPITAL: \$2.2 million  
 TOTAL ASSETS: \$5.4 million  
 NET WORTH: \$2.7 million

All figures as of March 31, 2007

### RECENT NEWS HEADLINES

Thu, May 31, 2007

Pluristem announced today that its fully owned subsidiary Pluristem Ltd has received a competitive research and development grant of about \$830,000 from Israel's prestigious Chief Scientist Office. The 3% royalty-bearing grant is part of the Government's Ministry of Trade and Industry program that offers incentives to high-tech companies for research and development. The grant will support Pluristem's goal to explore the use of placental expanded mesenchymal stem (PLX) cells for various clinical indications.

Tue, May 22, 2007

Pluristem has closed on a private equity investment in the Company totaling approximately \$13.5 million. The financing will be used to complete the development of the company's first product, PLX-I, and explore the use of its placental expanded mesenchymal stem (PLX) cells for other clinical indications.

### HEADQUARTERS

**Pluristem Life Systems, Inc.**  
 MATAM Advanced Technology Park  
 Building No. 20  
 Haifa 31905, Israel  
 Phone: 972-4-850-1080 Fax: 972-4-850-1085  
 Web Site: [www.pluristem.com](http://www.pluristem.com)  
 Email: [info@pluristem.com](mailto:info@pluristem.com)



The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. For complete disclaimer information, the reader is hereby referred to the Disclaimer Page of the Flaherty Financial News / WallStreet Research Small Cap Conference Book or the [www.WallStreetResearch.org](http://www.WallStreetResearch.org) website.